Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma

Oncotarget
Scott A EzellKate F Byth

Abstract

Agents that target components of the PI3K/AKT/mTOR pathway are under investigation for the treatment of diffuse large B cell lymphoma (DLBCL). Given the highly heterogeneous nature of DLBCL, it is not clear whether all subtypes of DLBCL will be susceptible to PI3K pathway inhibition, or which kinase within this pathway is the most favorable target. Pharmacological profiling of a panel of DLBCL cell lines revealed a subset of DLBCL that was resistant to AKT inhibition. Strikingly, sensitivity to AKT inhibitors correlated with the ability of these inhibitors to block phosphorylation of S6K1 and ribosomal protein S6. Cell lines resistant to AKT inhibition activated S6K1 independent of AKT either through upregulation of PIM2 or through activation by B cell receptor (BCR) signaling components. Finally, combined inhibition of AKT and BTK, PIM2, or S6K1 proved to be an effective strategy to overcome resistance to AKT inhibition in DLBCL.

References

Mar 26, 2003·Proceedings of the National Academy of Sciences of the United States of America·Melinda S GordonRandolph Wall
Aug 6, 2003·Proceedings of the National Academy of Sciences of the United States of America·George WrightLouis M Staudt
Mar 8, 2008·Science·Georg LenzLouis M Staudt
Sep 4, 2008·Proceedings of the National Academy of Sciences of the United States of America·Georg LenzLouis M Staudt
Mar 12, 2009·Cancer Biology & Therapy·Fengxue ZhangAndrew S Kraft
May 26, 2009·Nature Chemical Biology·Tatsuya OkuzumiKevan M Shokat
Jul 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Lee A HonigbergJoseph J Buggy
Dec 24, 2010·Nature·Vu N NgoLouis M Staudt
Sep 23, 2011·Blood·Cristina Gómez-AbadMiguel A Piris
Nov 9, 2011·Proceedings of the National Academy of Sciences of the United States of America·Sejeong ShinSang-Oh Yoon
Feb 5, 2013·Bioorganic & Medicinal Chemistry Letters·Kurt G PikeMartin Pass
Jul 11, 2013·Proceedings of the National Academy of Sciences of the United States of America·Matthias PfeiferGeorg Lenz
Dec 18, 2013·Pharmacology & Therapeutics·Jiri Polivka, Filip Janku
Jan 29, 2014·Proceedings of the National Academy of Sciences of the United States of America·Lesley A Mathews GrinerCraig J Thomas
May 2, 2014·Journal of Medicinal Chemistry·Kevin S CurrieScott A Mitchell
Jul 30, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mohamed RahmaniSteven Grant
Sep 13, 2014·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Agata MajchrzakPiotr Smolewski
Oct 3, 2014·Nature·Jagan R MuppidiJason G Cyster
Oct 11, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Margaret Veldman-JonesKenneth S Thress

❮ Previous
Next ❯

Citations

Mar 10, 2019·Bioinformatics·Di DuPhilip L Lorenzi
Feb 2, 2017·British Journal of Haematology·Teresa Calimeri, Andrés J M Ferreri
Feb 9, 2020·International Journal of Molecular Sciences·Chiara TarantelliFrancesco Bertoni
Sep 26, 2017·Molecular Medicine Reports·Wei DuGuochao Shi
Dec 20, 2018·Frontiers in Oncology·Jean-Ehrland Ricci, Johanna Chiche
Oct 11, 2020·Molecular Cancer Therapeutics·Peggy A ThompsonKevin R Webster
Jan 26, 2021·Frontiers in Oncology·Yimei FengXi Zhang
Jul 6, 2021·Frontiers in Oncology·Ricardo Rivera-SotoBlossom Damania

❮ Previous
Next ❯

Datasets Mentioned

BETA
GSE57083

Software Mentioned

package
gplots
R

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Adam M PetrichSamir Parekh
Zhonghua bing li xue za zhi Chinese journal of pathology
Tie-cheng ZhangDa-ren Shi
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Jin-Fan LiZhi-Gui Ma
© 2021 Meta ULC. All rights reserved